Literature DB >> 36194371

Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Mitra Behroozaghdam1,2, Maryam Dehghani2, Amirhossein Zabolian3, Davood Kamali4, Salar Javanshir5, Farzaneh Hasani Sadi6, Mehrdad Hashemi2, Teimour Tabari7, Mohsen Rashidi8,9, Sepideh Mirzaei10, Atefeh Zarepour11, Ali Zarrabi11, Danielle De Greef12, Anupam Bishayee13.   

Abstract

Breast cancer (BC) is one of the most common cancers in females and is responsible for the highest cancer-related deaths following lung cancer. The complex tumor microenvironment and the aggressive behavior, heterogenous nature, high proliferation rate, and ability to resist treatment are the most well-known features of BC. Accordingly, it is critical to find an effective therapeutic agent to overcome these deleterious features of BC. Resveratrol (RES) is a polyphenol and can be found in common foods, such as pistachios, peanuts, bilberries, blueberries, and grapes. It has been used as a therapeutic agent for various diseases, such as diabetes, cardiovascular diseases, inflammation, and cancer. The anticancer mechanisms of RES in regard to breast cancer include the inhibition of cell proliferation, and reduction of cell viability, invasion, and metastasis. In addition, the synergistic effects of RES in combination with other chemotherapeutic agents, such as docetaxel, paclitaxel, cisplatin, and/or doxorubicin may contribute to enhancing the anticancer properties of RES on BC cells. Although, it demonstrates promising therapeutic features, the low water solubility of RES limits its use, suggesting the use of delivery systems to improve its bioavailability. Several types of nano drug delivery systems have therefore been introduced as good candidates for RES delivery. Due to RES's promising potential as a chemopreventive and chemotherapeutic agent for BC, this review aims to explore the anticancer mechanisms of RES using the most up to date research and addresses the effects of using nanomaterials as delivery systems to improve the anticancer properties of RES.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Apoptosis; Breast cancer; Drug resistance; Nano-scale delivery; Radiotherapy; Resveratrol

Mesh:

Substances:

Year:  2022        PMID: 36194371     DOI: 10.1007/s00018-022-04551-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  199 in total

Review 1.  Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations.

Authors:  Rokaya El Ansari; Alan McIntyre; Madeleine L Craze; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Histopathology       Date:  2017-10-17       Impact factor: 5.087

2.  Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells.

Authors:  Lian Liu; Kwang Seok Ahn; Muthu K Shanmugam; Hong Wang; Hongyuan Shen; Frank Arfuso; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Yung Chang; Gautam Sethi; Feng Ru Tang
Journal:  J Cell Biochem       Date:  2018-09-27       Impact factor: 4.429

Review 3.  Potential role of targeted therapies in the treatment of triple-negative breast cancer.

Authors:  Lee Yueh Jia; Muthu K Shanmugam; Gautam Sethi; Anupam Bishayee
Journal:  Anticancer Drugs       Date:  2016-03       Impact factor: 2.248

Review 4.  A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.

Authors:  Qing-Yun Chong; Ze-Hui Kok; Ngoc-Linh-Chi Bui; Xiaoqiang Xiang; Andrea Li-Ann Wong; Wei-Peng Yong; Gautam Sethi; Peter E Lobie; Lingzhi Wang; Boon-Cher Goh
Journal:  Pharmacol Res       Date:  2020-02-14       Impact factor: 7.658

5.  PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.

Authors:  Luxi Chen; Yi Yuan; Shreya Kar; Madhu M Kanchi; Suruchi Arora; Ji E Kim; Pei F Koh; Einas Yousef; Ramar P Samy; Muthu K Shanmugam; Tuan Z Tan; Sung W Shin; Frank Arfuso; Han M Shen; Henry Yang; Boon C Goh; Joo I Park; Louis Gaboury; Peter E Lobie; Gautam Sethi; Lina H K Lim; Alan P Kumar
Journal:  Mol Cancer Ther       Date:  2017-08-15       Impact factor: 6.261

6.  Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.

Authors:  Qi Wu; Juanjuan Li; Shan Zhu; Juan Wu; Chuang Chen; Qian Liu; Wen Wei; Yimin Zhang; Shengrong Sun
Journal:  Oncotarget       Date:  2017-04-25

Review 7.  The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.

Authors:  Stephanie L Goff; David N Danforth
Journal:  Clin Breast Cancer       Date:  2020-07-02       Impact factor: 3.225

Review 8.  Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis.

Authors:  Krishan K Thakur; Aviral Kumar; Kishore Banik; Elika Verma; Elina Khatoon; Choudhary Harsha; Gautam Sethi; Subash C Gupta; Ajaikumar B Kunnumakkara
Journal:  J Cell Physiol       Date:  2021-06-08       Impact factor: 6.384

9.  Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway.

Authors:  Chakrabhavi Dhananjaya Mohan; V Srinivasa; Shobith Rangappa; Lewis Mervin; Surender Mohan; Shardul Paricharak; Sefer Baday; Feng Li; Muthu K Shanmugam; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Andreas Bender; Gautam Sethi; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

10.  Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.

Authors:  Wenquan Lu; Zhen Ni; Shuqin Jiang; Mingfu Tong; Jian Zhang; Jing Zhao; Chenchen Feng; Qiaoyu Jia; Jingyun Wang; Tingting Yao; Hanbing Ning; Yongquan Shi
Journal:  Phytother Res       Date:  2020-10-25       Impact factor: 5.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.